+

WO2006060533A3 - Conjugates of 1, 8-bis-naphthalimides with an antibody - Google Patents

Conjugates of 1, 8-bis-naphthalimides with an antibody Download PDF

Info

Publication number
WO2006060533A3
WO2006060533A3 PCT/US2005/043409 US2005043409W WO2006060533A3 WO 2006060533 A3 WO2006060533 A3 WO 2006060533A3 US 2005043409 W US2005043409 W US 2005043409W WO 2006060533 A3 WO2006060533 A3 WO 2006060533A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
adc
formula
relates
bis
Prior art date
Application number
PCT/US2005/043409
Other languages
French (fr)
Other versions
WO2006060533A2 (en
Inventor
Lewis J Gazzard
Edward Hyungsuk Ha
David Y Jackson
Joann Um
Original Assignee
Genentech Inc
Lewis J Gazzard
Edward Hyungsuk Ha
David Y Jackson
Joann Um
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Lewis J Gazzard, Edward Hyungsuk Ha, David Y Jackson, Joann Um filed Critical Genentech Inc
Priority to EP05852595A priority Critical patent/EP1817059A2/en
Priority to JP2007544495A priority patent/JP4993645B2/en
Publication of WO2006060533A2 publication Critical patent/WO2006060533A2/en
Publication of WO2006060533A3 publication Critical patent/WO2006060533A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to antibody drug conjugate (ADC) compounds represented by Formula:(I) where one or more 1,8 bis-naphthalimide drug moieties (D) having Formulas (IIa) and (Ilb)are covalently linked by a linker (L) to an antibody (Ab). The invention also relates to pharmaceutical compositions comprising an effective amount of a Formula I ADC for treatment of hyperproliferative disorders and other disorders. The invention also relates to methods for killing or inhibiting the multiplication of a tumor cell or cancer cell including administering to a patient an effective amount of a Formula (I) ADC.
PCT/US2005/043409 2004-12-01 2005-11-29 Conjugates of 1, 8-bis-naphthalimides with an antibody WO2006060533A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05852595A EP1817059A2 (en) 2004-12-01 2005-11-29 Conjugates of 1,8-bis-naphthalimides with an antibody
JP2007544495A JP4993645B2 (en) 2004-12-01 2005-11-29 Antibody drug conjugates and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63261304P 2004-12-01 2004-12-01
US60/632,613 2004-12-01

Publications (2)

Publication Number Publication Date
WO2006060533A2 WO2006060533A2 (en) 2006-06-08
WO2006060533A3 true WO2006060533A3 (en) 2007-07-26

Family

ID=36263731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/043409 WO2006060533A2 (en) 2004-12-01 2005-11-29 Conjugates of 1, 8-bis-naphthalimides with an antibody

Country Status (3)

Country Link
EP (1) EP1817059A2 (en)
JP (1) JP4993645B2 (en)
WO (1) WO2006060533A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8562693B2 (en) 2006-03-24 2013-10-22 L'oreal Method of dyeing and lightening keratin materials in the presence of a reducing agent comprising a fluorescent deisulphide dye
US8911732B2 (en) 2010-12-20 2014-12-16 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
US9056910B2 (en) 2012-05-01 2015-06-16 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates
US9175089B2 (en) 2012-03-30 2015-11-03 Genentech, Inc. Anti-LGR5 antibodies and immunoconjugates
US9453078B2 (en) 2009-01-12 2016-09-27 Cytomx Therapeutics, Inc. Modified antibody compositions, methods of making and using thereof

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
US20070134243A1 (en) * 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
FR2898902B1 (en) * 2006-03-24 2010-09-10 Oreal PARTICULAR DYES OF THE NAPHTHALIMIDE TYPE, TINCTORIAL COMPOSITION COMPRISING AT LEAST ONE SUCH COLOR, PROCESS FOR CARRYING OUT AND USES
EP2024444B1 (en) * 2006-03-24 2011-07-06 L'Oréal Dyeing composition containing a thiol/disulphide naphthylimide fluorescent colorant, and method for lightening keratin materials using said colorant
ATE518916T1 (en) 2006-03-24 2011-08-15 Oreal DYEING COMPOSITION WITH A THIOL/DISULFIDE FLUORESCENT DYE WITH A HETEROCYCLE AND AN INTERNAL CATIONIC CHARGE AND METHOD FOR LIGHTENING KERATIN MATERIAL WITH THIS DYE
EP2069308B1 (en) * 2006-09-12 2017-03-29 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Azonafide derived tumor and cancer targeting compounds
US8088378B2 (en) 2007-07-16 2012-01-03 Genetech Inc. Anti-CD79B antibodies and immunoconjugates and methods of use
WO2009012256A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
FR2921377B1 (en) 2007-09-21 2009-10-30 Oreal STYRYL COMPOUND HAVING HYDROXY (CYCLO) ALKYLAMINO THIOL / DISULFIDE PATTERN, PROCESS FOR LIGHTENING KERATINIC MATERIALS THEREFROM
FR2921381B1 (en) 2007-09-21 2009-10-30 Oreal HEMICYANINE STYRYLE THIOL / DISULFIDE DYE, TINCTORIAL COMPOSITION COMPRISING THE DYE, METHOD OF CLEANING KERATINIC MATERIALS FROM THAT COLORANT
FR2921376B1 (en) 2007-09-21 2009-10-30 Oreal STYRYL TETRAHYDROQUINOLINIUM THIOL / DISULFIDE COMPOUND, PROCESS FOR CLEANING KERATINIC MATERIALS FROM THAT COLORANT
FR2921373B1 (en) 2007-09-21 2009-10-30 Oreal LINK ALKYLENE STYRYL INDOLE DERIVATIVE DYE, TINCTORIAL COMPOSITION COMPRISING THE DYE, METHOD FOR LIGHTENING KERATINIC MATERIALS FROM THAT COLORANT
US8119656B2 (en) 2007-12-07 2012-02-21 The Board Of Regents Of The University Of Texas System Inhibitors of the influenza virus non-structural 1 protein
WO2009089537A2 (en) * 2008-01-11 2009-07-16 Northwestern University Anti-cancer compounds
MX2010008437A (en) 2008-01-31 2010-11-25 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use.
WO2009144205A1 (en) 2008-05-30 2009-12-03 Basf Se Rylene-based semiconductor materials and methods of preparation and use thereof
CA2787657A1 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP6642940B2 (en) * 2012-05-02 2020-02-12 ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド Aromatic dispersant composition
JP6280103B2 (en) 2012-05-15 2018-02-14 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Drug conjugate, conjugation method and use thereof
AU2013266604B2 (en) 2012-05-21 2016-09-08 Genentech, Inc. Anti-Ly6E antibodies and immunoconjugates and methods of use
CN104717979A (en) 2012-08-02 2015-06-17 基因泰克公司 Anti-ETBR antibodies and immunoconjugates
JP2015529656A (en) 2012-08-02 2015-10-08 ジェネンテック， インコーポレイテッド Anti-ETBR antibodies and immune complexes
CN103013497A (en) * 2012-12-21 2013-04-03 武汉大学 Sulfydryl fluorescent probe and preparation method thereof
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
KR20160055252A (en) 2013-09-17 2016-05-17 제넨테크, 인크. Methods of using anti-lgr5 antibodies
JP6707445B2 (en) 2013-10-21 2020-06-10 ジェネンテック， インコーポレイテッド Anti-Ly6E antibody and method of use
DK3262071T3 (en) 2014-09-23 2020-06-15 Hoffmann La Roche Method of using anti-CD79b immune conjugates
EP3165237B1 (en) 2015-11-03 2018-12-19 Industrial Technology Research Institute Antibody-drug conjugate (adc) and method for forming the same
TR201618160A2 (en) * 2016-12-09 2018-06-21 T C Istanbul Medipol Ueniversitesi SPECIAL DRUG MOLECULES SUITABLE FOR USE IN THE TREATMENT OF PARASITIC AND NEOPLASTIC DISEASES AND PROCEDURES FOR THE PREPARATION OF THEIR
JOP20190254A1 (en) 2017-04-27 2019-10-27 Pharma Mar Sa Antitumoral compounds
CN107625771B (en) * 2017-09-27 2018-12-14 徐州玖胜医疗器械有限公司 A kind of miR-17 gene inhibitor and the purposes for treating gastric cancer
TWI824043B (en) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 Drug antibody conjugates
WO2021043951A1 (en) 2019-09-05 2021-03-11 Pharma Mar, S.A. Drug antibody conjugates
IL297028A (en) 2020-04-21 2022-12-01 Pharma Mar Sa Drug-antibody conjugates
CN116063284A (en) * 2023-02-10 2023-05-05 河南大学 A class of gut-restricted TGR5 agonists containing a fragment covalently bound to mucin and its application in the treatment of diabetes drugs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005365A1 (en) * 1993-08-18 1995-02-23 Basf Aktiengesellschaft New bis-naphthalimides for the treatment of cancer
WO1996003384A1 (en) * 1994-07-22 1996-02-08 Ctrc Research Foundation Bis-naphthalimides with linkers having heteroatoms and uses thereof
US5641782A (en) * 1995-02-16 1997-06-24 The Dupont Merck Pharmaceutical Company 3-aromatic and 3-heteroaromatic substituted bisnaphthalimides
US20030216309A1 (en) * 2001-10-12 2003-11-20 University Of Vermont And State Agricultural College Binding peptides specific for the extracellular domain of ErbB2 and uses therefor

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
DE3707651A1 (en) 1987-03-10 1988-09-22 Knoll Ag BIS-NAPHTHALIMIDES, THEIR PRODUCTION AND USE
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (en) 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody.
US5416089A (en) 1993-06-24 1995-05-16 The Du Pont Merck Pharmaceutical Company Polycyclic and heterocyclic chromophores for bis-imide tumoricidals
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
MX9800684A (en) 1995-07-27 1998-04-30 Genentech Inc Stabile isotonic lyophilized protein formulation.
JP3646191B2 (en) 1996-03-19 2005-05-11 大塚製薬株式会社 Human gene
EP1226177B1 (en) 1999-10-29 2008-07-09 Genentech, Inc. Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
CA2393126C (en) 1999-11-29 2016-05-24 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20040005561A1 (en) 2000-03-01 2004-01-08 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2002016581A2 (en) 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2001270118A1 (en) 2000-08-24 2002-03-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2005506033A (en) 2000-10-13 2005-03-03 イーオーエス バイオテクノロジー インコーポレイテッド Prostate cancer diagnostic method, prostate cancer modulator screening composition and method
US20020159986A1 (en) 2001-01-12 2002-10-31 John Langenfeld Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
WO2002098358A2 (en) 2001-06-04 2002-12-12 Eos Biotechnology, Inc. Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
AU2002320264B2 (en) 2001-06-05 2008-05-01 Exelixis, Inc. GFATs as modifiers of the p53 pathway and methods of use
EP1517998A2 (en) 2001-06-18 2005-03-30 EOS Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7189507B2 (en) 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
EP2000545B1 (en) 2001-06-20 2011-08-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of lung tumor
AU2002337657A1 (en) 2001-07-25 2003-02-17 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
EP2174953A1 (en) 2001-09-18 2010-04-14 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002362454A1 (en) 2001-10-03 2003-04-14 Origene Technologies, Inc. Regulated breast cancer genes
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20050238650A1 (en) 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
DE60217152T2 (en) 2001-10-31 2007-10-31 Alcon Inc. BONE MORPHOGENIC PROTEINS (BMP), BMP RECEPTORS AND BMP BINDING PROTEINS AND THEIR USE IN DIAGNOSIS AND TREATMENT OF GLUCKOM
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20030134790A1 (en) 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
CA2480404A1 (en) 2002-03-25 2003-10-30 Uab Research Foundation Fc receptor homolog, reagents, and uses thereof
US20040249130A1 (en) 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
JP2005533794A (en) 2002-06-18 2005-11-10 アーケミックス コーポレイション Aptamer-toxin molecules and methods of using the same
AU2003259913A1 (en) 2002-08-19 2004-03-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
JP2004113151A (en) 2002-09-27 2004-04-15 Sankyo Co Ltd Oncogene and its application
ES2388280T3 (en) 2002-12-20 2012-10-11 Abbott Biotherapeutics Corp. Antibodies that react to GPR64 and use them
US20050227301A1 (en) 2003-01-10 2005-10-13 Polgen Cell cycle progression proteins
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
JP2009520459A (en) 2003-02-14 2009-05-28 サイグレス ディスカバリー， インコーポレイテッド Therapeutic target in cancer
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
PT2489364E (en) 2003-11-06 2015-04-16 Seattle Genetics Inc Monomethylvaline compounds conjugated to antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005365A1 (en) * 1993-08-18 1995-02-23 Basf Aktiengesellschaft New bis-naphthalimides for the treatment of cancer
WO1996003384A1 (en) * 1994-07-22 1996-02-08 Ctrc Research Foundation Bis-naphthalimides with linkers having heteroatoms and uses thereof
US5641782A (en) * 1995-02-16 1997-06-24 The Dupont Merck Pharmaceutical Company 3-aromatic and 3-heteroaromatic substituted bisnaphthalimides
US20030216309A1 (en) * 2001-10-12 2003-11-20 University Of Vermont And State Agricultural College Binding peptides specific for the extracellular domain of ErbB2 and uses therefor

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BAILLY CHRISTIAN ET AL: "Chromophore-modified bisnaphthalimides: DNA recognition, topoisomerase inhibition, and cytotoxic properties of two mono- and bisfuronaphthalimides.", BIOCHEMISTRY, vol. 42, no. 14, 15 April 2003 (2003-04-15), pages 4136 - 4150, XP002435351, ISSN: 0006-2960 *
BRANA M F ET AL: "Naphthalimides as anti-cancer agents: Synthesis and biological activity.", CURRENT MEDICINAL CHEMISTRY - ANTI-CANCER AGENTS, vol. 1, no. 3, November 2001 (2001-11-01), pages 237 - 255, XP008079357, ISSN: 1568-0118 *
BRANA M F ET AL: "SYNTHESIS, BIOLOGICAL ACTIVITY, AND QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP STUDY OF AZANAPHTHALIMIDE AND ARYLNAPHTHALIMIDE DERIVATIVES", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 47, no. 9, 2004, pages 2236 - 2242, XP008060139, ISSN: 0022-2623 *
BRANA MIGUEL F ET AL: "New analogues of amonafide and elinafide, containing aromatic heterocycles: Synthesis, antitumor activity, molecular modeling, and DNA binding properties.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 47, no. 6, 11 March 2004 (2004-03-11), pages 1391 - 1399, XP002435350, ISSN: 0022-2623 *
CARRASCO C ET AL: "DNA sequence recognition by bispyrazinonaphthalimides antitumor agents", BIOCHEMISTRY 14 OCT 2003 UNITED STATES, vol. 42, no. 40, 14 October 2003 (2003-10-14), pages 11751 - 11761, XP002435352, ISSN: 0006-2960 *
CHARI R V J ET AL: "IMMUNOCONJUGATES CONTAINING NOVEL MAYTANSINOIDS: PORMISING ANTICANCER DRUGS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 52, no. 1, January 1992 (1992-01-01), pages 127 - 131, XP000453560, ISSN: 0008-5472 *
HARRIS M: "Monoclonal antibodies as therapeutic agents for cancer", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 5, no. 5, May 2004 (2004-05-01), pages 292 - 302, XP004808280, ISSN: 1470-2045 *
SURESH BABU MEKAPATI ET AL: "QSAR OF ANTICANCER COMPOUNDS. BIS(11-OXO-11H-INDENO Ä1,2-BÜQUINOLINE-6-CARBOXAMIDES), BIS(PHENAZINE-1-CARBOXAMIDES), AND BIS(NAPHTHALIMIDES)", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 9, no. 11, 2001, pages 2757 - 2762, XP008060138, ISSN: 0968-0896 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8562693B2 (en) 2006-03-24 2013-10-22 L'oreal Method of dyeing and lightening keratin materials in the presence of a reducing agent comprising a fluorescent deisulphide dye
US8685114B2 (en) 2006-03-24 2014-04-01 L'oreal Composition for dyeing and lightening keratin materials comprising a fluorescent deisulphide dye compound
US9453078B2 (en) 2009-01-12 2016-09-27 Cytomx Therapeutics, Inc. Modified antibody compositions, methods of making and using thereof
US8911732B2 (en) 2010-12-20 2014-12-16 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
US9175089B2 (en) 2012-03-30 2015-11-03 Genentech, Inc. Anti-LGR5 antibodies and immunoconjugates
US9056910B2 (en) 2012-05-01 2015-06-16 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates
US9597411B2 (en) 2012-05-01 2017-03-21 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates

Also Published As

Publication number Publication date
WO2006060533A2 (en) 2006-06-08
JP2008521920A (en) 2008-06-26
JP4993645B2 (en) 2012-08-08
EP1817059A2 (en) 2007-08-15

Similar Documents

Publication Publication Date Title
WO2006060533A3 (en) Conjugates of 1, 8-bis-naphthalimides with an antibody
WO2007064345A3 (en) Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
WO2008076333A3 (en) Polymer-drug conjugates with tether groups for controlled drug delivery
UA103758C2 (en) Insulin-oligomer conjugates, formulations and uses thereof
WO2005117986A3 (en) Antibody drug conjugates and methods
CY1114941T1 (en) CYCLODEX-based MULTILATERAL BASED FOR ADMINISTRATION OF THERAPEUTICALLY COMMITTED MEDICINES
WO2007100385A3 (en) Macrocyclic depsipeptide antibody-drug conjugates and methods
WO2009016516A3 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
WO2005072061A3 (en) Conjugates for cancer therapy and diagnosis
NZ600039A (en) Biocompatible biodegradable fumagillin analog conjugates
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
WO2007100902A3 (en) Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
NZ745069A (en) Pyrrolobenzodiazepines and conjugates thereof
HK1102991A1 (en) Pharmaceutical formulation of decitabine
HK1107816A1 (en) Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer meleimide
BR0112589A (en) Heteroaryl derivatives and their application as a medicine
WO2007106544A3 (en) Chelating conjugates having a substituted aromatic moiety and derivatives thereof
HK1123728A1 (en) Immuno-rna-constructs
WO2005115470A3 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING β-CARBOLINE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER
RS20080002A (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
NZ593438A (en) Synthesis of polymer conjugates of indolocarbazole compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007544495

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005852595

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005852595

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载